Hepatotoxicity of mild analgesics

Area of Science:

• Pharmacology
• Hepatology
• Toxicology

Background:

• Hepatotoxicity from mild analgesics is uncommon at standard therapeutic doses.
• Recent recognition of hepatotoxicity potential for aspirin and salicylates.
• Salicylate hepatitis often presents asymptomatically with elevated aminotransferases, particularly in young patients with connective tissue diseases on long-term, high-dose therapy.

Purpose of the Study:

• To review the hepatotoxic potential of common analgesics.
• To highlight risks associated with specific drugs like salicylates and paracetamol.
• To discuss management strategies for analgesic-induced liver injury.

Main Methods:

• Literature review of analgesic-induced hepatotoxicity.
• Analysis of case reports and clinical studies.
• Examination of toxicological mechanisms and treatment outcomes.

Main Results:

• Aspirin and salicylates can cause hepatotoxicity, especially with prolonged high-dose use in specific populations.
• Acute paracetamol (acetaminophen) overdose can result in fatal hepatic necrosis, with treatment efficacy dependent on timing.
• Chronic paracetamol use is a rare potential cause of chronic hepatitis; phenacetin shows no clear evidence of hepatotoxicity in humans.
• Phenylbutazone and other analgesics may cause liver injury or hypersensitivity reactions.

Conclusions:

• While rare, hepatotoxicity is a recognized risk with certain analgesics, particularly with overdose or prolonged high-dose use.
• Early recognition and intervention are critical for managing severe cases like paracetamol-induced liver injury.
• Clinicians should be aware of the potential for liver damage from various analgesics and monitor patients accordingly.